173 related articles for article (PubMed ID: 38415559)
1. Clinical assessment of TGFB1 and HP Relative Gene Expression in the Peripheral Blood of Prostate Cancer Patients.
Yahya MS; Abdel Hameed FF; Radwan NH; Abdelgawad IA; Soliman AF
Asian Pac J Cancer Prev; 2024 Feb; 25(2):709-717. PubMed ID: 38415559
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
4. Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population.
Omrani MD; Taghipour-Bazargani S; Salari-Lak S; Bagheri M
Urol Int; 2009; 83(3):329-32. PubMed ID: 19829035
[TBL] [Abstract][Full Text] [Related]
5. Haptoglobin polymorphism is not associated with prostate cancer in blacks.
Mavondo GA; Mangena Z; Kasvosve I
Clin Chim Acta; 2012 Jan; 413(1-2):334-6. PubMed ID: 21986563
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta 1 gene polymorphisms and expression in the blood of prostate cancer patients.
Faria PC; Saba K; Neves AF; Cordeiro ER; Marangoni K; Freitas DG; Goulart LR
Cancer Invest; 2007 Dec; 25(8):726-32. PubMed ID: 18058470
[TBL] [Abstract][Full Text] [Related]
7. TUG1 promotes the development of prostate cancer by regulating RLIM.
Guo BH; Zhao Q; Li HY
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
[TBL] [Abstract][Full Text] [Related]
8. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
9. The Diagnostic Value of Serum TGF-β1, p2PSA Combined with PSA in Prostate Cancer.
Guo X; Sun X; Ye P
Altern Ther Health Med; 2023 Nov; ():. PubMed ID: 37971439
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
Rezatabar S; Moudi E; Sadeghi F; Khafri S; Kopi TA; Parsian H
J Gene Med; 2020 Oct; 22(10):e3239. PubMed ID: 32529802
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
12. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
13. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
14. [Influence of histological prostatitis on the clinical features of benign prostatic hyperplasia and prostate cancer].
Zhang F; Si-Mu-Jiang-Abula A; Zhang LD
Zhonghua Nan Ke Xue; 2014 Apr; 20(4):354-8. PubMed ID: 24873164
[TBL] [Abstract][Full Text] [Related]
15. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
Fu S; Zhang X; Niu Y; Wang RT
Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
[TBL] [Abstract][Full Text] [Related]
16. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
17. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
18. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
19. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
20. Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer.
Fryczkowski M; Bułdak RJ; Hejmo T; Kukla M; Żwirska-Korczala K
Dis Markers; 2018; 2018():3852401. PubMed ID: 30186533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
